Clinical trial · Interventional
Study of Natural Killer Cells in Patients With Metastatic Prostate Cancer: Relationship With Survival and Response Time to Castration
Prospective Study of Natural Killer Cells in Patients With Metastatic Prostate Cancer: Relationship With Survival and Response Time to Castration
NCT02963155CI-TRIAL-00042685NKPROSTATEunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective research of Natural Killer cells as predictive biomarkers to stratify patients likely to have longer response time to castration.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Prostate Cancer | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Metastatic prostate cancer blood samples
- interventionNames
- Other: Blood samples
Primary outcomes (2)
- measure
- Response time to castration
- timeFrame
- every 6 months during 3 years-follow up
- description
- Time of occurrence of: * confirmed PSA rise + serum testosterone \< 0.50 ng/mL * and/or radiological progression according to the modified PCWG2 criteria (progression according to the RECIST criteria v1.1 or documented by the appearance of at least 2 new lesions on the bone scan)
- measure
- Survival
- timeFrame
- every 6 months during 3 and 5 years-follow up
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient with metastatic prostate cancer. 2. Aged of 18 years or more. 3. Patient in period of sensitivity to castration (patient non castrated or castration performed less than 1 year ago) and lack of progression. 4. Patient having signed an informed consent. 5. Patient affiliated to the national "Social Security" regimen or beneficiary of this regimen. Exclusion Criteria: 1. Patient under chemotherapy treatment at the time of sampling 2. Patient under corticotherapy treatment at the time of sampling 3. Patient in emergency situation, adult subject to a measure of legal protection (placed under judicial protection, tutorship, or curatorship), or unable to give consent. 4. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study medical follow-up 5. Contraindications to study procedure
References
Publications (3)
- BACKGROUNDPasero C, Gravis G, Granjeaud S, Guerin M, Thomassin-Piana J, Rocchi P, Salem N, Walz J, Moretta A, Olive D. Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer. Oncotarget. 2015 Jun 10;6(16):14360-73. doi: 10.18632/oncotarget.3965. PMID 25961317
- BACKGROUNDGannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods. 2009 Aug 31;348(1-2):9-17. doi: 10.1016/j.jim.2009.06.004. Epub 2009 Jun 22. PMID 19552894
- BACKGROUNDMamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Goncalves A, Andre P, Romagne F, Thibault G, Viens P, Birnbaum D, Bertucci F, Moretta A, Olive D. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011 Sep;121(9):3609-22. doi: 10.1172/JCI45816. Epub 2011 Aug 15. PMID 21841316